ArticleFrontiers in immunology2024

Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.

Guiyuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.